Comparison of Autologous Quadriceps and Hamstring Tendon Grafts in Anterior Cruciate Ligament Reconstruction
Launched by MUZAFFER AGIR · Sep 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different types of tendon grafts used in surgery to repair a torn anterior cruciate ligament (ACL) in the knee. Specifically, it is comparing the use of grafts taken from the quadriceps tendon (the muscle at the front of the thigh) to those taken from the hamstring tendon (located at the back of the thigh). Researchers are interested in understanding which method leads to better recovery and outcomes for patients after surgery.
If you are an elite or amateur athlete between the ages of 18 and 74 who has suffered an ACL injury, you may be eligible to participate in this study. However, those who have had previous surgeries on the same knee or other significant knee injuries may not qualify. Participants in this trial can expect to undergo surgery and will be monitored to see how well they recover over time. This is an exciting opportunity to contribute to important research that could improve treatment options for ACL injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Elite athletes
- • Amateur athletes
- • Anterior cruciate ligament injury
- Exclusion Criteria:
- • Revision surgery
- • Another ligament injury ( medial collateral ligament, lateral collateral ligament, etc.. )
- • \> Grade-2 cartilage injury
- • Having previously undergone surgery on the same knee
- • \< 18 years age
About Muzaffer Agir
Muzaffer Agir is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, the organization specializes in designing and conducting clinical trials across various therapeutic areas. Muzaffer Agir collaborates with a network of leading healthcare professionals and institutions to ensure the highest quality of data and compliance with regulatory requirements, ultimately striving to bring new treatments to the market that enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported